Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATHE Alterity Therapeutics Limited

Early Closed 12-24 13:00:00 EST

2.45

+0.05

+2.08%

盘后2.45

+0.000.00%

16:49 EST

High2.60	Low2.40	Vol37.47K
Open2.40	D1 Closing2.40	Amplitude8.13%
Mkt Cap21.72M	Tradable Cap19.30M	Total Shares8.87M
T/O93.17K	T/O Rate0.48%	Tradable Shares7.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ATHE","market":"US","secType":"STK","nameCN":"Alterity Therapeutics Limited","latestPrice":2.45,"timestamp":1735063200000,"preClose":2.4,"halted":0,"volume":37474,"hourTrading":{"tag":"盘后","latestPrice":2.45,"preClose":2.45,"latestTime":"16:49 EST","volume":99,"amount":245.25,"timestamp":1735076955023},"delay":0,"floatShares":7878500,"shares":8867226,"eps":-2.097678,"marketStatus":"Early Closed","change":0.05,"latestTime":"12-24 13:00:00 EST","open":2.4,"high":2.595,"low":2.4,"amount":93174.42799220001,"amplitude":0.08125,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.097678,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735203600000},"marketStatusCode":6,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":2.4,"preHourTrading":{"tag":"盘前","latestPrice":2.4892,"preClose":2.4,"latestTime":"08:36 EST","volume":4869,"amount":11842.201647,"timestamp":1735047404179},"postHourTrading":{"tag":"盘后","latestPrice":2.45,"preClose":2.45,"latestTime":"16:49 EST","volume":99,"amount":245.25,"timestamp":1735076955023},"volumeRatio":1.951308},"requestUrl":"/m/hq/s/ATHE/tweets","defaultTab":"tweets","newsList":[{"id":"2491339984","title":"Alterity Therapeutics Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2491339984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491339984?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:53","pubTimestamp":1734022380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATHE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2024 11:53 ET (16:53 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067","ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2488198729","title":"Alterity Therapeutics completes last patient visit in ATH434-201 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488198729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488198729?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:40","pubTimestamp":1733316025,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, double-blind, placebo-controlled invest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-completes-last-patient-visit-in-ath434-201-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-completes-last-patient-visit-in-ath434-201-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2488602651","title":"Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488602651","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488602651?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:35","pubTimestamp":1733315700,"startTime":"0","endTime":"0","summary":"– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australiaand SAN FRANCISCO, Dec.  04, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991393/0/en/Alterity-Therapeutics-Completes-Last-Patient-Visit-in-ATH434-201-Phase-2-Clinical-Trial-in-Early-Stage-Multiple-System-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","LU1923622291.USD","LU2125909916.SGD","SSI","BK4143","BK4139","ATHE","LU0053671581.USD","LU1815336091.USD","WRD","LU0728928796.USD","LENZ","LU0757428866.USD","MSA"],"gpt_icon":0},{"id":"2484943145","title":"Alterity Therapeutics appoints Abby Macnish Niven as secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2484943145","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484943145?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:30","pubTimestamp":1732019423,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as CFO o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-appoints-abby-macnish-niven-as-secretary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-appoints-abby-macnish-niven-as-secretary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2484439479","title":"Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2484439479","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484439479?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:25","pubTimestamp":1732019100,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Nov.  19, 2024  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/19/2983468/0/en/Alterity-Therapeutics-Appoints-Abby-Macnish-Niven-as-Company-Secretary.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","ATHE"],"gpt_icon":1},{"id":"2482674706","title":"Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2482674706","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482674706?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:35","pubTimestamp":1731414900,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024  -- Alterity Therapeutics  , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy  natural history study at the 35th International Symposium on the Autonomic Nervous System.The platform presentation entitled, “The MSA Atrophy Index: A Marker of Clinical Progression in Multiple System Atrophy”, was presented by Paula Trujillo Diaz, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center.Biomarkers of progression in Multiple System Atrophy  is a natural history study that aims to track the progression of individuals with MSA, a parkinsonian disorder without approved therapy. The study is being conducted in collaboration with Vanderbilt University Medical Center in the U.S. under the direction of Daniel Claassen, M.D., M.S., Profess","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hHCqqEwtANkFUjQIhiWPHw--~B/aD01Njt3PTIyMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e21f1e2bcd82d8889ade6f7680933e97","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hHCqqEwtANkFUjQIhiWPHw--~B/aD01Njt3PTIyMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e21f1e2bcd82d8889ade6f7680933e97"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-announces-presentation-tracking-123500373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0757428866.USD","ATH.AU","ATHE","LU0053671581.USD","WRD","MSA","BK4023","BK4143","LU1169590202.USD","LU1923622291.USD","LU1815336091.USD","LU2125909759.SGD","PD","LU2125909916.SGD","LU0728928796.USD","LENZ","BK4139","LU1169589451.USD"],"gpt_icon":0},{"id":"2481603016","title":"Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434","url":"https://stock-news.laohu8.com/highlight/detail?id=2481603016","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481603016?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:35","pubTimestamp":1730896500,"startTime":"0","endTime":"0","summary":"– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov.  06, 2024  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975628/0/en/Alterity-Therapeutics-Announces-New-Publication-Describing-Novel-Mechanism-of-Action-for-ATH434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0757428866.USD","LU1815336091.USD","MSA","LU2125909759.SGD","LU0053671581.USD","ATHE","LU2125909916.SGD","BK4143","LU1923622291.USD","LU0728928796.USD","LENZ"],"gpt_icon":1},{"id":"2479970704","title":"Appendix 4C – Q1 FY25 Quarterly Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2479970704","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479970704?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:35","pubTimestamp":1730374500,"startTime":"0","endTime":"0","summary":"Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025. Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System Atrophy. Multiple data presentations at the International Congress of Parkinson’s Disease and Movement Disorders . Appointed Abby Macnish Niven as Chief Financial Officer. “Last month, we delivered multiple presentations at the International Congress of Parkinson’s Disease and Movement Disorders , a prominent neurology meeting. At this event, we presented clinical and preclinical data demonstrating the potential of ATH434 in a variety of neurological conditions including early-stage MSA, advanced MSA, and Parkinson’s disease. We look forward to presenting additional data at medical meetings, and the topline results from both our ATH434-201 and ATH434-202 trials in calendar year 2025,” added, Dr. Stamler.On 17 July 2024, Alte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hHCqqEwtANkFUjQIhiWPHw--~B/aD01Njt3PTIyMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e21f1e2bcd82d8889ade6f7680933e97","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hHCqqEwtANkFUjQIhiWPHw--~B/aD01Njt3PTIyMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e21f1e2bcd82d8889ade6f7680933e97"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/appendix-4c-q1-fy25-quarterly-113500639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125909759.SGD","LU1923622291.USD","LU2125909916.SGD","ATH.AU","BK4143","BK4139","ATHE","LU0053671581.USD","LU1815336091.USD","LU0728928796.USD","LU0757428866.USD","MSA"],"gpt_icon":1},{"id":"2475504293","title":"Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475504293","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475504293?lang=en_us&edition=fundamental","pubTime":"2024-10-14 19:35","pubTimestamp":1728905700,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Oct.  14, 2024  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/14/2962471/0/en/Alterity-Therapeutics-to-Participate-in-a-Fireside-Chat-at-the-2024-Maxim-Healthcare-Virtual-Summit-on-17-October-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","LENZ","SMMF","BK4139","ATHE","HCSG","BK4137"],"gpt_icon":0},{"id":"2474067748","title":"Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2474067748","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474067748?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:35","pubTimestamp":1728646500,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Oct.  11, 2024  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/11/2961955/0/en/Alterity-Therapeutics-Announces-Presentation-of-New-Data-Describing-Neuroprotection-of-ATH434-at-Neuroscience-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2125909916.SGD","LENZ","LU1923622291.USD","MSA","LU2125909759.SGD","BK4143","LU0728928796.USD","ATHE","LU0757428866.USD","LU1815336091.USD","LU0053671581.USD"],"gpt_icon":0},{"id":"2472741549","title":"Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®","url":"https://stock-news.laohu8.com/highlight/detail?id=2472741549","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472741549?lang=en_us&edition=fundamental","pubTime":"2024-10-02 19:35","pubTimestamp":1727868900,"startTime":"0","endTime":"0","summary":"- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Aust","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/02/2956861/0/en/Alterity-Therapeutics-Raises-Profile-with-Multiple-Data-Presentations-at-the-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU2125909916.SGD","BK4139","LU0053671581.USD","BK4143","LU1923622291.USD","LENZ","LU0757428866.USD","ATHE","LU0728928796.USD","LU2125909759.SGD","LU1169589451.USD","MSA","LU1169590202.USD","BK4023","LU1815336091.USD"],"gpt_icon":0},{"id":"2471809735","title":"Alterity Therapeutics Appoints Abby Niven as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2471809735","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471809735?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:58","pubTimestamp":1727697517,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  said on Monday it appointed Abby Niven to succeed Phillip Hains as chief financial officer, effective today.Niven has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett and consults on governance, finance, and corporate structure for various companies.Hains continues as company secretary.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2471161806","title":"Press Release: Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2471161806","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471161806?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:35","pubTimestamp":1727696100,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024  -- Alterity Therapeutics  , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company's Chief Financial Officer , effective today.\"We look forward to Abby's contributions whose broad experience and financial background will help us advance our programs. I would also like to express my gratitude to Phillip and his team who supported us during a transition period,\" said David Stamler, M.D., Chief Executive Officer of Alterity.Ms Macnish Niven has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate structure. Ms Macnish Niven holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.Ms Macnish Niv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHE","BK4139","LENZ","CFO","BK7067","ATH.AU"],"gpt_icon":0},{"id":"2469197451","title":"Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®","url":"https://stock-news.laohu8.com/highlight/detail?id=2469197451","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469197451?lang=en_us&edition=fundamental","pubTime":"2024-09-23 19:35","pubTimestamp":1727091300,"startTime":"0","endTime":"0","summary":"- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept.  ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/23/2951289/0/en/Alterity-Therapeutics-to-Deliver-Multiple-Oral-and-Poster-Presentations-at-the-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSA","PD","LU1169589451.USD","LU1169590202.USD","BK4143","LU0053671581.USD","LU0728928796.USD","LU2125909759.SGD","BK4023","LU1923622291.USD","LU2125909916.SGD","LU1815336091.USD","LENZ","LU0757428866.USD","ATHE","BK4139"],"gpt_icon":0},{"id":"2468164702","title":"Alterity Therapeutics Directors’ Holdings Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2468164702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468164702?lang=en_us&edition=fundamental","pubTime":"2024-09-20 20:27","pubTimestamp":1726835252,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has released an update. Alterity Therapeutics Limited has reported a change in the interest of directors Mr. Brian Mel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-directors-holdings-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-directors-holdings-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ"],"gpt_icon":0},{"id":"2456438488","title":"Alterity Therapeutics Options Expire Unexercised","url":"https://stock-news.laohu8.com/highlight/detail?id=2456438488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456438488?lang=en_us&edition=fundamental","pubTime":"2024-08-01 19:31","pubTimestamp":1722511878,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) has released an update. Alterity Therapeutics Limited announced the expiration of 12 million options, coded ATHAAF, pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-options-expire-unexercised?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-options-expire-unexercised?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","ATHE"],"gpt_icon":0},{"id":"2455848061","title":"Appendix 4C – Q4 FY24 Quarterly Cash Flow Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2455848061","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455848061?lang=en_us&edition=fundamental","pubTime":"2024-07-31 19:35","pubTimestamp":1722425700,"startTime":"0","endTime":"0","summary":"Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in some","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/31/2921783/0/en/Appendix-4C-Q4-FY24-Quarterly-Cash-Flow-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4178","MSA","LU2125909759.SGD","LU1815336091.USD","ATHE","BK4143","LU0053671581.USD","BK4139","LU1923622291.USD","LU0728928796.USD","AAN","LU0757428866.USD","LU2125909916.SGD"],"gpt_icon":0},{"id":"2453003772","title":"Alterity Therapeutics to Present at MST Financial Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2453003772","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453003772?lang=en_us&edition=fundamental","pubTime":"2024-07-24 19:35","pubTimestamp":1721820900,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, July  24, 2024  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/24/2917914/0/en/Alterity-Therapeutics-to-Present-at-MST-Financial-Webinar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","ATHE"],"gpt_icon":0},{"id":"2452026431","title":"Alterity (ATHE) Up on Interim Data From Advance MSA Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2452026431","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452026431?lang=en_us&edition=fundamental","pubTime":"2024-07-18 23:01","pubTimestamp":1721314860,"startTime":"0","endTime":"0","summary":"Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy , a rare neurodegenerative disease. The study enrolled 10 participants with advanced MSA.Per the press company, interim analysis results from the open-label ATH434-202 study included clinical and biomarker data from seven participants who were treated with ATH434 for six months and neuroimaging data from three participants who were treated with ATH434 for 12 months.In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have narrowed from 14 cents to 13 cents. Loss per share estimates for 2025 have narrowed from $3.44 to $3.21. Year to date, shares of TRDA have jumped 13.4%.In the past 60 days, estimates for Compugen’s 2024 earnings per share have improved from 2 cents to 5 cents, while loss per share estimates for 2025 have na","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-athe-interim-data-advance-150100589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XAIR","LU1815336091.USD","LU1923622291.USD","LU2125909759.SGD","BK4121","LU0757428866.USD","MSA","ATHE","ATH.AU","LU0053671581.USD","LU0728928796.USD","BK4082","BK4143","BK4139","CGEN","LU2125909916.SGD","TRDA"],"gpt_icon":0},{"id":"2452198968","title":"Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2452198968","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452198968?lang=en_us&edition=fundamental","pubTime":"2024-07-18 01:39","pubTimestamp":1721237942,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in patients with multiple system atrophy.Interim data showed that out of seven MSA patients who have completed six months of ATH434 treatment, three had reduced disability and two had stable or improved neurological symptoms, according to Alterity.The drug was generally well-tolerated with no serious adverse events reported, the company said.Although the data are preliminary, the company said it sees a \"positive trend\" with the outcomes.Price: 2.25, Change: +0.27, Percent Change: +13.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATHE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alteritytherapeutics.com","stockEarnings":[{"period":"1week","weight":0.039},{"period":"1month","weight":1.243},{"period":"3month","weight":0.9124},{"period":"6month","weight":0.3472},{"period":"1year","weight":-0.1011},{"period":"ytd","weight":-0.0361}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0014},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2555},{"period":"ytd","weight":0.2512}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.081222},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.064525},{"month":3,"riseRate":0.409091,"avgChangeRate":0.005611},{"month":4,"riseRate":0.5,"avgChangeRate":-0.019094},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.055947},{"month":6,"riseRate":0.318182,"avgChangeRate":0.026025},{"month":7,"riseRate":0.545455,"avgChangeRate":0.089249},{"month":8,"riseRate":0.590909,"avgChangeRate":0.068907},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.035667},{"month":10,"riseRate":0.304348,"avgChangeRate":-0.073881},{"month":11,"riseRate":0.434783,"avgChangeRate":-0.016008},{"month":12,"riseRate":0.304348,"avgChangeRate":0.006373}],"exchange":"NASDAQ","name":"Alterity Therapeutics Limited","nameEN":"Alterity Therapeutics Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alterity Therapeutics Limited,ATHE,Alterity Therapeutics Limited股票,Alterity Therapeutics Limited股票老虎,Alterity Therapeutics Limited股票老虎国际,Alterity Therapeutics Limited行情,Alterity Therapeutics Limited股票行情,Alterity Therapeutics Limited股价,Alterity Therapeutics Limited股市,Alterity Therapeutics Limited股票价格,Alterity Therapeutics Limited股票交易,Alterity Therapeutics Limited股票购买,Alterity Therapeutics Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}